Press Release, A4C News
Rachel Splinter
Project PROTECT Milestone: U.S. Supply of ...

Angels for Change is proud to announce a major Project PROTECT milestone: our partner Fagron Sterile Services is now fully production-ready with new U.S. capacity for Sterile Water for Injection—a critical component used in countless injectable medicines.

This marks the second successful Project PROTECT collaboration with Fagron, following earlier investments that helped protect patients during the IV fluid shortage in 2024. By investing in domestic manufacturing infrastructure, we’re strengthening the resilience of the U.S. drug supply and protecting patients before shortages occur.

We don’t just talk about ending drug shortages—we’re creating solutions that build onshore readiness, strengthen supply chains, and protect patient access to lifesaving medicines.

Project PROTECT Milestone: U.S. Supply of Sterile Water for Injection Protected
In the News
Rachel Splinter
Laura Bray Featured in APIIC White Paper on ...

Laura Bray and Angels for Change highlighted in the newly released white paper from the API Innovation Center, “Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.”

Bray emphasized a clear call to action for leaders across the healthcare ecosystem to work together to solve the drug shortage crisis:

“This is not the patient’s job to solve at all… This is a supply chain failure.”

Laura Bray Featured in APIIC White Paper on Strengthening the Drug Supply Chain
Rachel Splinter
Angels for Change and Project GOLD highlighted ...

Drug shortages are making national headlines again as families search for critical medicines like leucovorin. In a recent CNN article, Angels for Change founder Laura Bray highlights how the crisis was predictable—and preventable. Through Project GOLD, Angels for Change works across the supply chain to locate scarce medications and help patients access the treatments they depend on, because no family should have to face a shortage alone.

Angels for Change and Project GOLD highlighted in CNN article about the current Leucovorin Drug Shortage in the U.S.
Rachel Splinter
Angels for Change serves as Advising Member in ...

At Angels for Change, we are proud to participate in the important work of the End Drug Shortages Alliance — serving as both an EDSA member organization and advising partner in the Drug Resiliency & Transparency Pilot.

The initial phase of the pilot demonstrated a powerful truth: when leaders come together early through trusted, neutral governance, transparency delivers real planning value.

Angels for Change serves as Advising Member in the Drug Resiliency & Transparency Pilot
A4C News, Press Release
Rachel Splinter
Project PROTECT Milestone: Angels for Change ...

Angels for Change today announced that the Mark Cuban Cost Plus Drug Company has completed the Preparation and Protective phases of Project PROTECT for Carboplatin Injection and Methotrexate Injection—two essential oncology medicines currently in nationwide shortage. This milestone strengthens onshore readiness and improves supply availability for patients across the United States.

Project PROTECT Milestone: Angels for Change and Mark Cuban Cost Plus Drug Company have Strengthened the U.S. Supply of Carboplatin & Methotrexate

A4C News

,

Project PROTECT Milestone: U.S. Supply of Sterile Water for Injection Protected

,
Project PROTECT Milestone: U.S. Supply of Sterile Water for Injection Protected

Angels for Change is proud to announce a major Project PROTECT milestone: our partner Fagron Sterile Services is now fully production-ready with new U.S. capacity for Sterile Water for Injection—a critical component used in countless injectable medicines.

This marks the second successful Project PROTECT collaboration with Fagron, following earlier investments that helped protect patients during the IV fluid shortage in 2024. By investing in domestic manufacturing infrastructure, we’re strengthening the resilience of the U.S. drug supply and protecting patients before shortages occur.

We don’t just talk about ending drug shortages—we’re creating solutions that build onshore readiness, strengthen supply chains, and protect patient access to lifesaving medicines.

,

Project PROTECT Milestone: Angels for Change and Mark Cuban Cost Plus Drug Company have Strengthened the U.S. Supply of Carboplatin & Methotrexate

,
Project PROTECT Milestone: Angels for Change and Mark Cuban Cost Plus Drug Company have Strengthened the U.S. Supply of Carboplatin & Methotrexate

Angels for Change today announced that the Mark Cuban Cost Plus Drug Company has completed the Preparation and Protective phases of Project PROTECT for Carboplatin Injection and Methotrexate Injection—two essential oncology medicines currently in nationwide shortage. This milestone strengthens onshore readiness and improves supply availability for patients across the United States.

Angels for Change Convenes First Ever SummitONE PolicyLAB to Drive Action on the U.S. Drug Shortage Crisis

Angels for Change Convenes First Ever SummitONE PolicyLAB to Drive Action on the U.S. Drug Shortage Crisis

New from Angels for Change: the launch of our Policy Lab.

The A4C Policy Lab brings together patients, clinicians, policymakers, and industry leaders to turn frontline experience into actionable policy solutions that address drug shortages at their root.

Last week on January 29th, 2026, Angels for Change convened a sold-out National Policy Lab on Capitol Hill in the historic Kennedy Caucus Room to tackle one of the most urgent issues in healthcare: the U.S. drug shortage crisis.

Angels for Change is translating patient harm into real-world policy solutions. This Policy Lab wasn’t a conference — it was a working session focused on collaboration, candor, and outcomes, with patients at the center of every solution.

2025 Year in Review

2025 Year in Review

Angels for Change — 2025 Year in Review

From supporting patients through dozens of different shortage crisis to launching a first-of-its-kind oncology resiliency program to shaping national policy conversations, 2025 was a year of bold action and patient-driven progress.

Together with partners across healthcare, government, and industry, we:

  • Protected patients during critical drug shortages

  • Launched Project GOLD to proactively safeguard cancer care

  • Protected 4 addition essential medicines for the American people with Project PROTECT 

  • Elevated patient voices in policy and supply chain reform

  • Built momentum toward a more resilient medicine supply system

See how collaboration, transparency, and patient leadership are driving lasting change.

Project PROTECT Milestone to Strengthen U.S. Supply of Magnesium Sulfate

Project PROTECT Milestone to Strengthen U.S. Supply of Magnesium Sulfate

Angels for Change’s Project PROTECT has taken a significant step to strengthen preparedness for a lifesaving medicine, magnesium sulfate. In partnership with STAQ Pharma, magnesium sulfate is now ready for on-demand production, reinforcing resilience for a medicine essential to protecting mothers and newborns during emergencies and supply strain. This proactive readiness ensures patients receive vital treatment without delay.

A4C Awards 2025 Change Maker of the Year

A4C Awards 2025 Change Maker of the Year

Angels for Change Honors 2025 Change Maker of the Year

Angels for Change has named Vimala Raghavendran, Vice President at the U.S. Pharmacopeia (USP), as the 2025 Change Maker of the Year. Raghavendran created the groundbreaking Medicine Supply Map, a first-of-its-kind tool used nationwide to uncover vulnerabilities in the medicine supply chain and prevent drug shortages.

Her innovation has powered lifesaving work at A4C and beyond — strengthening access to critical medicines and protecting patients.

A4C Formal Comments on Controlled Substances Forecasting

On August 27, 2025, Angels for Change was featured at the Reagan-Udall Foundation for the FDA’s Public Meeting on Demand Forecasting for Controlled Substances in Washington, DC. Our founder, Laura Bray, was a featured panelist.

In our public comments for the record, we highlighted how outdated and inflexible forecasting processes are leaving patients without access to critical medicines. We called for a more transparent, patient-centered approach that:

  • Anchors demand forecasting in real-world patient care rather than sales data

  • Brings together stakeholders across the supply chain, prescribers, and patient advocates

  • Builds regulatory flexibility to respond to changing patient needs

“We must anchor forecasting in patient care, reimbursement realities, and supply chain insight — not in sales numbers skewed by a constrained, quota-driven market.”

The panel discussion, moderated by Susan Winkler CEO of the Reagan-Udall foundation, brought together leaders from across healthcare to examine the challenges of forecasting controlled substances, the importance of accurate data, and the broader impact on patient access.

Read our full public comments submitted during the meeting below.

A4C Public Comments

2024 Annual Report

Angels for Change Releases 2024 Annual Report

Tampa, FL — Angels for Change has released its 2024 Annual Report, offering a comprehensive look at the organization’s impact over the past year in addressing drug shortages and advancing patient access across the pharmaceutical supply chain.

In a year that saw the highest number of drug shortages ever recorded—323 active shortages reported nationwide—Angels for Change remained committed to collaborative, systems-based solutions. The report outlines measurable progress across advocacy, policy engagement, emergency response, and supply chain resilience.

Key highlights include:

  • Over 750,000 treatments accessed through our Drug Shortage Hotline and Global Supply Sharing Network

  • A 98% success rate in addressing patient needs during active shortages

  • 9 essential medicines protected through Project PROTECT

  • Ongoing leadership on two federal task forces focused on drug shortages

  • National growth through media coverage, strategic partnerships, and grassroots engagement

As the only nonprofit patient advocacy organization solely focused on ending drug shortages, Angels for Change continues to drive change through cross-sector collaboration, policy leadership, and patient-centered action.

Read the full report to learn more about our 2024 impact and the work ahead.

View Annual Report

SHARE YOUR “WHY”

Every conversation, partnership, and shared story brings us closer to a future without drug shortages. At Angels for Change, we’re proud to march forth for patients everywhere.

SHARE YOUR STORY